Literature DB >> 1727900

Concurrent human immunodeficiency virus and mycobacterial infection of macrophages in vitro does not reveal any reciprocal effect.

P R Meylan1, J R Munis, D D Richman, R S Kornbluth.   

Abstract

To test whether in vitro infection of macrophages with either human immunodeficiency virus (HIV) or mycobacteria would influence the replication of the other pathogen, macrophages were infected sequentially with the macrophage-tropic isolate HTLV-IIIBa-L/85 and Mycobacterium tuberculosis H37Rv or Mycobacterium avium. The intracellular growth of mycobacteria was measured by colony counting and radiometric assay of macrophage lysates and the replication of HIV by the release of p24 antigen into the culture supernatants. Phagocytosis and intracellular growth of mycobacteria was similar in HIV-infected macrophages and controls. Conversely, mycobacteria did not affect the replication of HIV in macrophages. These experiments failed to demonstrate any direct intracellular interaction between HIV and mycobacteria in cultured macrophages that would explain the increased rate of mycobacterial diseases in patients infected with HIV or that would support the hypothesis that mycobacterial infection of macrophages per se can enhance HIV replication in these cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727900     DOI: 10.1093/infdis/165.1.80

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

2.  Effects of in vitro HIV-1 infection on mycobacterial growth in peripheral blood monocyte-derived macrophages.

Authors:  Sharad Pathak; Tore Wentzel-Larsen; Birgitta Asjö
Journal:  Infect Immun       Date:  2010-07-12       Impact factor: 3.441

Review 3.  Potential role of cytokines in disseminated mycobacterial infections.

Authors:  L E Bermudez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

4.  Entry and survival of Leishmania amazonensis amastigotes within phagolysosome-like vacuoles that shelter Coxiella burnetii in Chinese hamster ovary cells.

Authors:  P S Veras; C Moulia; C Dauguet; C T Tunis; M Thibon; M Rabinovitch
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients.

Authors:  Francesca Sabbatini; Alessandra Bandera; Giulio Ferrario; Daria Trabattoni; Giulia Marchetti; Fabio Franzetti; Mario Clerici; Andrea Gori
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

6.  Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.

Authors:  P R Meylan; R S Kornbluth; I Zbinden; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 7.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

8.  Interaction between human immunodeficiency virus and Toxoplasma gondii replication in dually infected monocytoid cells.

Authors:  Y Welker; J M Molina; C Poirot; F Ferchal; J M Decazes; P Lagrange; F Derouin
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Envelope glycoprotein (gp120) from HIV-1 enhances Mycobacterium avium growth in human bronchoalveolar macrophages; an effect mediated by enhanced prostaglandin synthesis.

Authors:  M Denis
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

10.  Modulation of the effector function of human monocytes for Mycobacterium avium by human immunodeficiency virus-1 envelope glycoprotein gp120.

Authors:  H Shiratsuchi; J L Johnson; Z Toossi; J J Ellner
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.